Imidazol-1-YL-oxo-acetic acid tert-butyl ester → 2-Amino-7-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3,6-dicarboxylic acid di-tert-butyl ester

HRID 1242081Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1242081
[C:1]([O:5][C:6]([C:8]1[C:16]2[CH2:15][CH:14]([CH2:17][N:18]3[C:26](=[O:27])[C:25]4[C:20](=[CH:21][CH:22]=[CH:23][C:24]=4OCC4C=CC=CC=4)[C:19]3=[O:36])[N:13]([C:37]([O:39][C:40]([CH3:43])([CH3:42])[CH3:41])=[O:38])[CH2:12][C:11]=2[S:10][C:9]=1[NH2:44])=[O:7])([CH3:4])([CH3:3])[CH3:2].[C:45]([O:49][C:50]([C:52]1[C:60]2[CH2:59][CH2:58][N:57]([C:61]([O:63][C:64]([CH3:67])([CH3:66])[CH3:65])=[O:62])[CH:56]([CH2:68][N:69]3[C:77](=[O:78])[C:76]4[C:71](=[CH:72][CH:73]=[CH:74][C:75]=4OCC4C=CC=CC=4)[C:70]3=[O:87])[C:55]=2[S:54][C:53]=1[NH2:88])=[O:51])([CH3:48])([CH3:47])[CH3:46].C(OC(=O)C(N1C=CN=C1)=O)(C)(C)C>ClCCl>[C:1]([O:5][C:6]([C:8]1[C:16]2[CH2:15][CH:14]([CH2:17][N:18]3[C:26](=[O:27])[C:25]4[C:20](=[CH:21][CH:22]=[CH:23][CH:24]=4)[C:19]3=[O:36])[N:13]([C:37]([O:39][C:40]([CH3:43])([CH3:42])[CH3:41])=[O:38])[CH2:12][C:11]=2[S:10][C:9]=1[NH2:44])=[O:7])([CH3:3])([CH3:4])[CH3:2].[C:45]([O:49][C:50]([C:52]1[C:60]2[CH2:59][CH2:58][N:57]([C:61]([O:63][C:64]([CH3:66])([CH3:67])[CH3:65])=[O:62])[CH:56]([CH2:68][N:69]3[C:70](=[O:87])[C:71]4[C:76](=[CH:75][CH:74]=[CH:73][CH:72]=4)[C:77]3=[O:78])[C:55]=2[S:54][C:53]=1[NH2:88])=[O:51])([CH3:46])([CH3:47])[CH3:48]

Komponenten

6

Versuchsvorschrift

To a solution of the above mixture of 2-amino-5-(4-benzyloxy-1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3,6-dicarboxylic acid di-tert-butyl ester and 2-amino-7-(4-benzyloxy-1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3,6-dicarboxylic acid di-tert-butyl ester (0.15 g, 0.24 mmol) in distilled dichloromethane (4 ml) under nitrogen was added imidazol-1-yl-oxo-acetic acid tert-butyl ester (0.14 g, 0.72 mmol) and the reaction mixture was stirred at ambient temperature for 1.5 h. The volatiles were evaporated in vacuo and the crude residue was purified by silica gel chromatography using dichloromethane as eluant. Pure fractions were collected and the solvent evaporated in vacuo affording 50 mg of 2-(tert-butoxyoxalyl-amino)- (4-benzyloxy-1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3,6-dicarboxylic acid di-tert-butyl ester (A) and 50 mg of 2-(tert-butoxyoxalyl-amino)-7-(4-benzyloxy-1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3,6-dicarboxylic acid di-tert-butyl ester (B). Another 50 mg remained as a mixture of the two isomers (A) and (B).

Aufarbeitung

  1. customThe volatiles were evaporated in vacuo
  2. customthe crude residue was purified by silica gel chromatography
  3. customPure fractions were collected
  4. customthe solvent evaporated in vacuo

Quellen und Nachweise

ORD-Eintrag
ord-0b5e8b7179aa424997bb35910786131e
Quelldatensatz
uspto-grants-2006_10
Patentnummer
US07115624B1

Notizen zur Reaktion

Wird geladen…